We believe in fighting diseases that others are afraid to tackle
Our Founding Philosophy
From 2002 to 2021, brain tumour research represented just 1% of the total UK cancer research spend (1,2). These diseases are often seen as too difficult to solve, so very few companies are willing to tackle them. This has created an opportunity as the science in this space has yet to meet modern technological advancements in biology and computing. We believe all the pieces for a breakthrough are ready and awaiting a technical group courageous enough to translate this opportunity into patient benefit.
Developments in biology and computing such as single-cell sequencing tools, lower genomic sequencing costs, hyperscale GPU computing and AI are aligning in a way reminiscent of last century’s transistor revolution. As a result, many relevant biological questions have transitioned from science problems to engineering problems. This transition will enable us to discover new drugs for many patients with brain diseases in our lifetime.
Science first
We start in the clinic and work backwards to create our technology
We have deep clinical and scientific expertise, which allows us to comprehensively understand our problem space. We see polymathic AI as a tool that enables our scientists to do qualitatively better science.
We build technology to solve specific problems, rather than starting with the technology and looking for problems to solve. This way, we work backwards from the clinic and pull together the tools we need to help our patients.
We build technology to solve specific problems, rather than starting with the technology and looking for problems to solve. This way, we work backwards from the clinic and pull together the tools we need to help our patients.
mission & values
To push the boundaries of science and technology to help patients with under served diseases of the brain.
Courage
When the odds are against us, the problem’s importance means we must try anyway. We are not afraid to confront difficult challenges.
Anti-fragility
True strength emerges through challenge. Anti-fragility means embracing change, learning from pressure, and evolving to become more resilient.
Urgency
The faster we move, the faster we can get new therapies to patients in need. Every delay impacts real patients.
Ownership
Accountability drives excellence. Ownership means caring deeply about outcomes, following through, and empowering others to do the same.
Candour
We speak with integrity—sharing ideas, feedback, and concerns directly and constructively. We believe transparency builds trust, strengthens teams, and drives better decisions.
Sources
OUR LABS
We are strategically located to combine technical talent from the UK golden triangle with US business ambition.
Our computational lab is based in London and our experimental lab is based in Cambridge, UK. Our strategic advisors are based in New York, Seattle, and California.
Cosyne Therapeutics
Medius House,
2 Sheraton Street,
London W1F 8BH
2 Sheraton Street,
London W1F 8BH
Cosyne Therapeutics
Milner Therapeutics Institute,
Jeffrey Cheah Biomedical Centre,
Puddicombe Way,
Cambridge, CB2 0AW
Jeffrey Cheah Biomedical Centre,
Puddicombe Way,
Cambridge, CB2 0AW